CTOR

Citius Oncology, Inc. Common Stock
CTOR

0.9450 USD
-0.0850
8.25%
At close Oct 9, 4:00 PM EDT
After hours
0.9450
+0.0000
0.00%
1 day
-8.25%
5 days
-29.48%
1 month
-45.69%
3 months
-70.47%
6 months
-70.47%
Year to date
-70.47%
1 year
-70.47%
5 years
-70.47%
 

About: Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

Healthcare Pharmaceutical Preparations
–
Funds holding %
of 6,740 funds
–
Analysts bullish %

Fund manager confidence

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$6
535%
upside
Avg. target
$6
535%
upside
High target
$6
535%
upside

1 analyst rating

1 positive
100%
0 neutral
0%
0 negative
0%
EF Hutton
Jason Kolbert
32% 1-year accuracy
15 / 47 met price target
535%upside
$6
Buy
Maintained
13 Aug 2024
See Analyst Rankings

Financial journalist opinion

We haven’t received any recent news articles for CTOR.

See News Rankings
Charts implemented using Lightweight Charts™